Genvor (GNVR)

At the Virtual Investor Conferences Life Science Investor Forum in December 2025, Genvor, Inc. (OTCQB: $GNVR ) CEO Chad Pawlak discussed why peptides represent a new era in agricultural biologicals, one that has the potential to deliver on long-standing industry promises. Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. Pawlak traced the evolution of biological crop protection to today’s third generation: peptides, proteins, and enzymes. “And now I believe we’re at that third level, third generation of biologicals, which include peptides, proteins, and enzymes. And what everybody’s so excited about is we have the opportunity to bring forward biological solutions that have the efficacy of synthetic chemistry, but the value proposition that we’ve been promising the world with biologicals for a very, very long time.” Genvor’s peptide portfolio spans four proprietary peptide classes, each targeting a different grower need: - AMPs: Broad-spectrum pathogen control - SEPs: Stress tolerance and nutrient uptake efficiency - NEPs: Nutritional enhancement (increasing protein content in animal feed rations) - Insecticidal peptides: Targeted insect mitigation Watch the clip: https://youtu.be/nYs0nZriOx0 The full presentation is available at: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5169307/genvor-inc-otcqb-gnvr Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. $GNVR $AGTECH $AGBIO $FOODSECURITY $BIOTECH $OTC $SMALLCAP

$GNVR $GNVR

Genvor, Inc. (OTCQB: $GNVR) announced today that peer-reviewed research validating its proprietary AGM182 antifungal peptide technology has been published in PhytoFrontiers, a journal of the American Phytopathological Society. The study was conducted in collaboration with the USDA Agricultural Research Service (USDA-ARS). Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. Greenhouse trial results showed transgenic corn expressing the BioCypher-designed AGM182 peptide achieved pre-harvest resistance to Aspergillus flavus and aflatoxin contamination, including: • 76-98% reduction in total aflatoxin contamination • No adverse effects on plant growth or yield • Proven mammalian safety profile with no observed toxicity • Activity against both Aspergillus flavus and Fusarium species Aflatoxins are toxic, carcinogenic compounds that contaminate corn and other crops. Economic losses from fungal diseases in corn are estimated between $3 billion and $5 billion annually. The publication follows the November 2025 issuance of U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both IP protection and independent scientific validation. The research builds on Genvor's 7+ year Cooperative Research and Development Agreement (CRADA) with USDA-ARS, conducted at the Food and Feed Safety Research Unit in New Orleans in collaboration with scientists from Tuskegee University. Dr. Jesse Jaynes, Professor of Biochemistry at Tuskegee University and founding scientist behind Genvor's core technologies, noted, "This publication represents the culmination of years of collaborative research between our team and the USDA. Seeing AGM182 validated through rigorous peer review in PhytoFrontiers confirms that computationally designed peptides can provide durable, safe, and scalable solutions for pre-harvest crop protection. This is precisely the kind of translational impact we set out to achieve." Read the full press release: https://genvor.com/press-releases/post?webmasterId=131326&qmodStoryID=6435559059692249 Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. 👉 $GNVR $AGTECH $AGBIO $FOODSECURITY $BIOTECH $OTC $SMALLCAP

At the Virtual Investor Conferences (OTC Markets Group) Life Science Investor Forum in December 2025, Genvor, Inc. (OTCQB: $GNVR ) CEO Chad Pawlak introduced the company’s AI-accelerated peptide platform and its focus on addressing urgent challenges in global agriculture. Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. Plant pathogens cause over $220 billion in lost crop yields annually, and growers face mounting pressure from regulators seeking softer chemistries and consumers demanding residue-free foods. Pawlak outlined how Genvor’s peptide-based approach is positioned to address both challenges. “Today, my goal is to introduce you to Genvor’s AI accelerated peptide platform and how we are positioning to address really one of the most urgent global challenges in agriculture today. And that’s crop disease. But in addition to that, associated with that, of course, is food security and the shift towards safer residue-free biological solutions.” Pawlak also discussed investor participation through the company’s current Reg D offering and ongoing partnership discussions with major agricultural companies. The presentation also highlighted the agricultural biologicals market opportunity: - Over $220 billion in annual crop losses from plant pathogens - Fast-track EPA review option available for peptides - No residue concerns for export markets - Organic capability depending on peptide design - Market growing from $9.5 billion toward $20 billion Watch the clip: https://youtu.be/hXohMmCUxyw See the full presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5169307/genvor-inc-otcqb-gnvr Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. $AGTECH $AGBIO $AI $FOODSECURITY $OTC $SMALLCAP

Woodland, California-based Genvor Inc., (OTCQB: $GNVR ), a pioneer in AI-accelerated peptide technology for sustainable agriculture, announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally, quadrupling revenues over a seven-year period. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Chad Pawlak, Sr., Chief Executive of Genvor, noted, “George’s track record of building successful commercial partnerships and bringing biological technologies to market at a global scale makes him the ideal leader to accelerate Genvor’s commercialization efforts. His deep expertise in evaluating and executing strategic collaborations combined with his hands-on experience scaling biocontrol portfolios will be instrumental as we advance discussions with major agricultural companies and bring our peptide-based solutions to growers worldwide.” See the full news release at: https://genvor.com/press-releases/post?storyId=8908158096018770 Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

$GNVR 👏

Woodland, California-based Genvor Inc. (OTC: $GNVR) announced that Co-Founder Dr. Clayton Yates will present at the 3rd Annual DealFlow Discovery Conference on January 28 at 11:00 AM EST at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. The presentation will focus on how Genvor’s AI-accelerated peptide platform is addressing plant pathogens that contribute to an estimated $220 billion in annual crop losses, offering investors insight into the company’s approach to sustainable, biological crop protection. Dr. Yates will discuss: • Genvor’s BioCypher platform, combining decades of peptide research with AI-driven discovery to develop biological actives for crop protection and plant health • Market opportunity addressing the global shift away from chemical inputs toward sustainable and regenerative agricultural practices • Partnership-first business model designed to keep the company capital-efficient while expanding its IP portfolio See the news release at: https://genvor.com/press-releases/post?storyId=7929758088949404 Dr. Yates is available for one-on-one meetings with investors throughout the two-day conference. Genvor is led by CEO Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.